Dermatol. praxi. 2020;14(1):6-8 | DOI: 10.36290/der.2020.001

Assessment of atopic eczema severity with EASI

MUDr. Filip Rob, Ph.D., prof. MUDr. Jana Hercogová, CSc.

Dermatovenerologická klinika 2. LF UK a Nemocnice Na Bulovce, Praha

Atopic eczema is a common chronic inflammatory disease that can significantly affect a patient's quality of life. Treatment options, particularly in severe forms of the disease, have been limited for a long time and largely included broad-spectrum immunosuppressive agents, such as cyclosporine, which, however, possess potential numerous adverse effects. The first biological therapy for atopic eczema has recently become available and other new drugs will follow in the years to come. Given the economic costs of novel modern drugs, the introduction of standardized scoring systems to objectively evaluate the efficacy of these drugs is becoming necessary. Currently, there are more than 25 different scoring systems for atopic dermatitis of which the Eczema Area and Severity Index (EASI) is required to assess the severity of and success rate of biological therapy for atopic dermatitis.

Keywords: atopic dermatitis, severity scoring, EASI, biologic therapy.

Published: March 25, 2020  Show citation